A gene within a gene contributes to the aggressiveness of acute myeloid leukemia

April 21, 2014, Ohio State University Medical Center

(Medical Xpress)—A small gene that is embedded in a larger, well-known gene is the true leukemia-promoting force usually attributed to the larger gene, according to a new study by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).

The findings are published in the journal Science Signaling.

The larger host gene is called BAALC (pronounced "Ball C"). The smaller embedded gene is called microRNA-3151 (miR-3151). The study investigated the degree to which each of the genes contributes to the development of acute myeloid leukemia (AML).

"We discovered that the smaller microRNA gene, and not the larger host gene, is the major oncogenic driver of the two molecules in AML," says principal investigator Albert de la Chapelle, MD, PhD, professor of Medicine and the Leonard J. Immke Jr. and Charlotte L. Immke Chair in Cancer Research.

"When both genes are highly expressed, it means a bad prognosis for patients, but our experiments indicate that it is high expression of miR-3151 that really matters. Overexpression of BAALC alone had only limited -causing activity," he says.

The researchers discovered that miR-3151 promotes the development of leukemia by blocking a gene called TP53. Normally, TP53 is a central "tumor-suppressor" gene that protects against cancer by causing a cell with serious gene damage to self-destruct. "When miR-3151 blocks TP53 in the tumor cells, it enables the cells to survive, divide and grow faster," says co-senior author Clara D. Bloomfield, MD, Distinguished University Professor and Ohio State University Cancer Scholar.

"We also show that miR-3151 promotes growth in malignant melanoma cells in the same way, suggesting that the molecule might play a role in solid-tumor development," says Bloomfield, who is also senior adviser to the OSUCCC – James and holds the William Greenville Pace III Endowed Chair in Cancer Research.

Last, the researchers show that miR-3151 overexpression may be inhibited by the drug bortezomib, a proteasome inhibitor, suggesting a possible therapy for miR-3151 overexpression.

MicroRNAs are a class of molecules that cells use to help regulate the kinds and amount of proteins they make. "About one-third of the several hundred known human microRNAs are encoded in host genes," says first author Ann-Kathrin Eisfeld, MD, a postdoctoral researcher who works in the laboratory of study co-authors de la Chapelle and Bloomfield.

Specifically, they are located in areas of genes called introns, short stretches of DNA that are not involved in making a protein. "We know very little about how microRNAs located within introns are regulated and how they interact with their ," Eisfeld says. "These findings provide an important example of that interaction."

The researchers found, for example, that miR-3151 has the capability to be active on its own, independent of the host gene.

For this study, de la Chapelle, Bloomfield, Eisfeld and their colleagues used human AML cells, cell lines and an animal model to investigate the overexpression of miR-3151 and BAALC in older patients with cytogenetically normal AML. Key technical findings include:

  • MiR-3151 directly targets PT53 and seven other in the TP53 pathway;
  • Overexpressing miR-3151 promotes AML-cell growth;
  • BAALC overexpression enhances that effect while blocking miR-3151 or overexpressing TP53 reverses it;
  • miR-3151 alone and in combination with BAALC promotes leukemia development in an animal model.

Explore further: A microRNA prognostic marker identified in acute leukemia

More information: Paper: stke.sciencemag.org/cgi/conten … /sigtrans;7/321/ra36

Listen here to a Science Signaling podcast featuring Eisfeld and de la Chapelle talking about this study.

Related Stories

A microRNA prognostic marker identified in acute leukemia

May 14, 2012
A study has identified microRNA-3151 as a new independent prognostic marker in certain patients with acute leukemia. The study involves patients with acute myeloid leukemia and normal-looking chromosomes (CN-AML).

Well-known cancer gene NRAS produces five variants, study finds

April 7, 2014
A new study shows that a gene discovered 30 years ago and now known to play a fundamental role in cancer development produces five different gene variants (called isoforms), rather than just the one original form, as thought.

Study identifies a likely key driver of colorectal cancer development and progression

April 14, 2014
A new study identifies a molecule that is a probable driving force in colorectal cancer and suggests that the molecule could be an important target for colorectal cancer treatment and a valuable biomarker of tumor progression.

Inherited DNA change explains overactive leukemia gene

May 25, 2012
A small inherited change in DNA is largely responsible for overactivating a gene linked to poor treatment response in people with acute leukemia.

Study identifies possible new acute leukemia marker, treatment target

May 13, 2013
A study has identified microRNA-155 as a new independent prognostic marker and treatment target in patients with acute myeloid leukemia that has normal-looking chromosomes under the microscope (that is, cytogenetically normal ...

MicroRNA molecule found to be a potent tumor-suppressor in lung cancer

September 16, 2013
New research shows that microRNA-486 is a potent tumor-suppressor molecule in lung cancer, and that the it helps regulate the proliferation and migration of lung-cancer cells, and the induction of programmed cell death, or ...

Recommended for you

Solving the mystery of NPM1 in acute myeloid leukemia

November 13, 2018
Although it has long been recognized that mutations of gene NPM1 play an important role in acute myeloid leukemia, no one has determined how the normal and the mutated forms of the protein NPM1 function.

Cognitive decline—radiation—brain tumor prevented by temporarily shutting down immune response

November 13, 2018
Treating brain tumors comes at a steep cost, especially for children. More than half of patients who endure radiation therapy for these tumors experience irreversible cognitive decline, a side-effect that has particularly ...

Study finds promising therapeutic target for aggressive type of breast cancer

November 13, 2018
A new Nature Communications study led by University of Kentucky Markey Cancer Center researchers suggests that an enzyme known as Prolyl 4-hydroxylase subunit alpha-1 (P4HA1) is a potential therapeutic target for triple negative ...

Scientists shine new light on link between obesity and cancer

November 12, 2018
Scientists have made a major discovery that shines a new, explanatory light on the link between obesity and cancer. Their research confirms why the body's immune surveillance systems—led by cancer-fighting Natural Killer ...

Obesity both feeds tumors and helps immunotherapy kill cancer

November 12, 2018
A groundbreaking new study by UC Davis researchers has uncovered why obesity both fuels cancer growth and allows blockbuster new immunotherapies to work better against those same tumors.

Two-pronged device enables maverick immune cells to identify and kill cancers

November 12, 2018
Immune cells called Gamma Delta T cells can act independently to identify and kill cancer cells, defying the conventional view of the immune system, reveals new research from the Francis Crick Institute and King's College ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.